CJC + Ipamorelin blend

Origin and structure

The blend contains two peptides in equal amounts: our vials hold 5 mg of CJC-1295 without DAC plus 5 mg of ipamorelin, or 10 mg of each. The two come from separate drug programmes and were never developed as a pair.

CJC-1295 was made by the Montreal company ConjuChem as a long-acting version of growth hormone-releasing hormone (GHRH), and tested in people in the mid-2000s. Its core is the first 29 amino acids of human GHRH, the same fragment as sermorelin, with four amino acids swapped to resist breakdown by enzymes. ConjuChem added a Drug Affinity Complex (DAC), a reactive group that binds the peptide to albumin in the blood and stretches its action from minutes to days. The peptide sold as CJC-1295 without DAC, also called modified GRF (1-29) or Mod GRF 1-29, is that 29-amino-acid core without the albumin anchor.

Ipamorelin came out of a chemistry programme at Novo Nordisk in Denmark and was described in 1998 as the first selective growth hormone secretagogue. It is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with unnatural amino acids, found in a series of compounds built from the older GH-releasing peptide GHRP-1 without its central Ala-Trp pair. It was later tested in hospital patients to speed recovery of the gut after bowel surgery, in two phase 2 trials; it never went further.

Which CJC-1295? The naming confusion

Strictly, CJC-1295 is the albumin-binding DAC molecule that ConjuChem took into trials. Every human study under that name used the DAC form: two placebo-controlled trials in healthy adults, a small uncontrolled study of night-time GH pulses in 12 healthy men, and a phase 2 trial in HIV lipodystrophy that was stopped in 2006. In healthy adults one injection of the DAC form had a half-life of 5.8 to 8.1 days.

The form without DAC first turns up in the scientific literature as an unknown preparation that Norwegian police and customs seized in 2009: analysis showed the CJC-1295 peptide chain, but no DAC.

None of the trial data transfers to the form in this blend. Without the albumin anchor the peptide is expected to be cleared far faster, but its half-life in people has never been measured. A 2026 review of GH-axis peptides found no peer-reviewed human study of CJC-1295 without DAC at all, and the FDA treated the two as separate substances when its compounding advisers voted on them in 2024. When a seller or a forum post cites CJC-1295 trial results, it is quoting data on a different molecule.

How it is thought to work

The two peptides push growth hormone release from different sides. CJC-1295 without DAC binds the GHRH receptor on the GH-producing cells of the pituitary. Ipamorelin activates the ghrelin receptor (GHS-R1a), a separate route that also ends in a GH pulse. In 12 healthy volunteers, an intravenous dose of GHRH together with the older ghrelin-receptor agonist GHRP-6 released more GH than the two given separately added up, and that is the idea behind the blend. For this particular pair the effect has never been measured; a 2026 review calls the rationale for combining them largely anecdotal.

Ipamorelin's selling point is selectivity. In a study in pigs, GHRP-2 and GHRP-6 pushed up the stress hormones ACTH and cortisol, while ipamorelin left them no higher than GHRH did, even at more than 200 times the dose that gave half the maximal GH response; none of the peptides changed LH, FSH, prolactin or TSH. In healthy men a single intravenous infusion produced one GH burst peaking at about 40 minutes, and ipamorelin had a half-life of about 2 hours.

Higher GH and IGF-1 levels are hormone markers, not outcomes. Neither component has been shown in a controlled trial to change muscle, fat, sleep or recovery in healthy people.

Is CJC-1295 with ipamorelin approved?

No. Neither peptide has ever been authorised as a medicine by the EMA or the FDA, and no regulator has assessed the combination. Without a marketing authorisation neither may be sold or advertised as a medicine in the Netherlands; the blend is sold only as research material, which is the basis our shop operates on.

In the United States both went through the FDA's review of substances that pharmacies wanted to compound, and both were turned down by its advisory committee:

In sport both are prohibited at all times. Section S2.2.4 of the 2026 WADA Prohibited List names CJC-1295 among the GHRH analogues and ipamorelin among the growth hormone secretagogues. The Dopingautoriteit publishes the same list in Dutch as the doping list in force from 1 January 2026, so the ban applies to Dutch athletes too.

• 29 October 2024: the Pharmacy Compounding Advisory Committee voted 0 in favour, 12 against, with 1 abstention, on adding ipamorelin (free base and acetate) to the list of substances US pharmacies may compound.
• 4 December 2024: the committee voted 0 to 13 on CJC-1295 without DAC as free base, 1 to 12 on its acetate salt, and 0 to 13 on each DAC form.
• The FDA's safety-risk page, last updated in April 2026, lists both among substances whose compounding nominations were withdrawn. It cites serious adverse events with CJC-1295 including a raised heart rate and a whole-body vasodilatory reaction, and deaths in an intravenous ipamorelin study. Ipamorelin acetate has also been in category 2 (significant safety risks) for outsourcing facilities since 29 September 2023.

What the research shows

There is no study of the blend. Everything below concerns one component on its own, and the CJC-1295 trials concern a different form of it.

• CJC-1295 with DAC, phase 1 (Teichman et al., 2006): two randomised, placebo-controlled trials of 28 and 49 days in healthy adults aged 21 to 61. A single injection raised mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9 to 11 days, and with repeated doses IGF-1 stayed above baseline for up to 28 days.
• CJC-1295 with DAC, phase 2: ConjuChem's placebo-controlled trial in HIV lipodystrophy had enrolled 192 patients when, in 2006, a participant developed chest pain about two hours after the 11th weekly dose and died of a heart attack. The treating physician thought silent coronary artery disease the most likely cause; the company ended the trial and no results were ever published.
• CJC-1295 without DAC: no published human study. A 2026 review placed it in its lowest evidence tier, with claims about GH pulses and body composition extrapolated from related compounds.
• Ipamorelin, phase 1 (Gobburu et al., 1999): a placebo-controlled dose-escalation study in which healthy men were given single 15-minute intravenous infusions at five dose levels; GH rose in a single burst, and the half-life was about 2 hours. It measured hormones, not any clinical effect.
• Ipamorelin, phase 2 (Beck et al., 2014): 114 patients analysed after bowel resection. Median time to a tolerated solid meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo (p = 0.15), and no key or secondary endpoint differed significantly. A second phase 2 trial in the same setting (NCT01280344) was completed in 2014 but its results were never published, and ipamorelin never reached phase 3.

Side effects and warnings

There are no safety data for the blend, and none for CJC-1295 without DAC in any form of human study. What is known comes from the components in other settings, so it shows what to watch for rather than what this product does.

In the single-dose CJC-1295 with DAC trial, 94% of those on the active drug reported an adverse event against 29% on placebo, none of them serious. About 70% had injection-site reactions, 63% headache (14% on placebo), 43% diarrhoea and 30% flushing, warmth or a brief drop in blood pressure, mostly at the two highest doses.

In the ipamorelin bowel-surgery trial, adverse events were about as frequent as on placebo (87.5% against 94.8%), but the FDA's review found low potassium (12.5% against 3.4%), insomnia (10.7% against 5.2%) and high blood sugar at discharge (14.3% against 8.6%) more often with ipamorelin. Two ipamorelin-treated patients died after a leak at the bowel join; the FDA calls the link to the drug unclear. For ipamorelin the agency also could not rule out the glucose intolerance and diabetes seen with approved products that stimulate GH release.

Frequently asked questions

Is CJC-1295 with ipamorelin legal in the Netherlands?

Neither peptide is a registered medicine, so the blend may not be sold or advertised as a medicine for human use. It is sold as research material, which is the basis our shop works on. Athletes are a separate matter: both peptides are on the doping list.

Has the combination been tested in humans?

No. No published study has given CJC-1295 without DAC and ipamorelin together, to people or to animals. Ipamorelin alone has phase 1 and phase 2 data; CJC-1295 without DAC has no human data of its own.

What is the difference between CJC-1295 with and without DAC?

Both share the same 29-amino-acid core. The DAC version carries an extra group that binds to albumin in the blood, which gave it a half-life of 5.8 to 8.1 days in trials. The version without DAC lacks that anchor; its half-life in people has never been measured, and none of the CJC-1295 trial results apply to it.

Why are CJC-1295 and ipamorelin combined?

Because they act on two different receptors that both trigger GH release. In a 1994 study in 12 healthy volunteers, GHRH plus the older peptide GHRP-6 released more GH than the two separately added together. Whether this pair does the same, or does anything lasting with repeated use, has not been studied.

Is CJC-1295 with ipamorelin banned in sport?

Yes, at all times, in and out of competition. The 2026 WADA Prohibited List names CJC-1295 and ipamorelin in section S2.2.4, and the Dopingautoriteit publishes that list in Dutch as the doping list that applies in the Netherlands.

Storage and handling

Store according to product-label instructions and batch handling notes. Lyophilized research peptides are commonly kept dry, protected from light, and handled with clean laboratory technique.

References

Checked against these sources on 28 October 2026.

Related peptides